These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 17418459)
1. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection. Carter KC; Henriquez FL; Campbell SA; Roberts CW; Nok A; Mullen AB; McFarlane E Vaccine; 2007 May; 25(22):4502-9. PubMed ID: 17418459 [TBL] [Abstract][Full Text] [Related]
2. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection. Henriquez FL; Campbell SA; Roberts CW; Mullen AB; Burchmore R; Carter KC J Parasitol; 2010 Oct; 96(5):929-36. PubMed ID: 20950100 [TBL] [Abstract][Full Text] [Related]
3. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection. Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224 [TBL] [Abstract][Full Text] [Related]
4. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Melby PC; Yang J; Zhao W; Perez LE; Cheng J Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143 [TBL] [Abstract][Full Text] [Related]
5. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection. Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110 [TBL] [Abstract][Full Text] [Related]
6. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani. Bhowmick S; Mazumdar T; Sinha R; Ali N J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373 [TBL] [Abstract][Full Text] [Related]
7. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Mazumdar T; Anam K; Ali N Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644 [TBL] [Abstract][Full Text] [Related]
8. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. Tewary P; Jain M; Sahani MH; Saxena S; Madhubala R J Infect Dis; 2005 Jun; 191(12):2130-7. PubMed ID: 15898000 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani. Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538 [TBL] [Abstract][Full Text] [Related]
10. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin. Mukherjee M; Bhattacharyya A; Duttagupta S Med Sci Monit; 2002 Apr; 8(4):BR117-22. PubMed ID: 11951057 [TBL] [Abstract][Full Text] [Related]
11. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis. Tewary P; Saxena S; Madhubala R Vaccine; 2006 Mar; 24(13):2409-16. PubMed ID: 16413950 [TBL] [Abstract][Full Text] [Related]
12. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10. Bhaumik SK; Naskar K; De T Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771 [TBL] [Abstract][Full Text] [Related]
13. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection. Daifalla NS; Bayih AG; Gedamu L Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023 [TBL] [Abstract][Full Text] [Related]
14. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis. Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606 [TBL] [Abstract][Full Text] [Related]
15. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis. Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900 [TBL] [Abstract][Full Text] [Related]
16. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis. Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458 [TBL] [Abstract][Full Text] [Related]
17. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice. Tonui WK; Titus RG Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887 [TBL] [Abstract][Full Text] [Related]
18. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475 [TBL] [Abstract][Full Text] [Related]
19. Leishmania donovani: identification of novel vaccine candidates using human reactive sera and cell lines. Arora SK; Pal NS; Mujtaba S Exp Parasitol; 2005 Mar; 109(3):163-70. PubMed ID: 15713447 [TBL] [Abstract][Full Text] [Related]
20. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis. Bhardwaj S; Vasishta RK; Arora SK Exp Parasitol; 2009 Jan; 121(1):29-37. PubMed ID: 18983842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]